世界のライソゾーム病治療市場規模・現状・予測（2021年-2027年）

• 英文タイトル：Global Lysosomal Disease Treatment Market Size, Status and Forecast 2021-2027

• レポートコード：QFJ1-5232
• 出版社/出版日：QYResearch / 2021年6月
※2024年版があります。お問い合わせください。
• レポート形態：英文、PDF、105ページ
• 納品方法：Eメール（納期：3日）
• 産業分類：医療機器

• 販売価格（消費税別）

Single User	￥585,000 (USD3,900)	▷ お問い合わせ
Multi User	￥877,500 (USD5,850)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

レポート概要

QYResearch社発行の本調査レポートでは、ライソゾーム病治療の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（造血幹細胞移植、酵素補充療法、基質減少、シャペロン療法）、用途別市場規模（病院、クリニック、幹細胞移植センター、研究機関、その他）、主要地域別市場規模（北米、アメリカ、欧州、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等）、企業情報などをまとめております。
・市場概要
・ライソゾーム病治療の市場動向
・企業の競争状況、市場シェア
・ライソゾーム病治療の種類別市場規模と予測2016-2027（造血幹細胞移植、酵素補充療法、基質減少、シャペロン療法）
・ライソゾーム病治療の用途別市場規模と予測2016-2027（病院、クリニック、幹細胞移植センター、研究機関、その他）
・ライソゾーム病治療の北米市場規模2016-2027（アメリカ、カナダ）
・ライソゾーム病治療の欧州市場規模2016-2027（ドイツ、フランス、イギリス等）
・ライソゾーム病治療のアジア市場規模2016-2027（日本、中国、韓国、インド、東南アジア等）
・ライソゾーム病治療の中南米市場規模2016-2027（メキシコ、ブラジル）
・ライソゾーム病治療の中東・アフリカ市場規模2016-2027（トルコ、サウジアラビア等）
・主要企業情報（Astellas Pharma、Astrazeneca、Actelion Pharmaceuticals Ltd.、Eli Lilly and Co.、Merck & Co.、Novo Nordisk A/S、Shire、Pfizer、Sanofi、BioMarin）
・結論

Lysosomal disease treatment is a way to alleviate Lysosomal storage disease.
Lysosomal disease is caused by defects in lysosomal function and degradation pathways. It is caused by the gradual accumulation of metabolites.

Market Analysis and Insights: Global Lysosomal Disease Treatment Market
The global Lysosomal Disease Treatment market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Lysosomal Disease Treatment market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Lysosomal Disease Treatment market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Lysosomal Disease Treatment market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Lysosomal Disease Treatment market.

Global Lysosomal Disease Treatment Scope and Market Size
Lysosomal Disease Treatment market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Lysosomal Disease Treatment market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.

Segment by Type
Hematopoietic Stem Cell Transplantation
Enzyme Replacement Therapy
Substrate Reduction
Chaperone Therapies

Segment by Application
Hospitals
Clinics
Stem Cell Transplant Center
Research Organizations
Others

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

By Company
Astellas Pharma
Astrazeneca
Actelion Pharmaceuticals Ltd.
Eli Lilly and Co.
Merck & Co.
Novo Nordisk A/S
Shire
Pfizer
Sanofi
BioMarin

レポート目次

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Lysosomal Disease Treatment Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Hematopoietic Stem Cell Transplantation
1.2.3 Enzyme Replacement Therapy
1.2.4 Substrate Reduction
1.2.5 Chaperone Therapies
1.3 Market by Application
1.3.1 Global Lysosomal Disease Treatment Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Stem Cell Transplant Center
1.3.5 Research Organizations
1.3.6 Others
1.4 Study Objectives
1.5 Years Considered

2 Global Growth Trends
2.1 Global Lysosomal Disease Treatment Market Perspective (2016-2027)
2.2 Lysosomal Disease Treatment Growth Trends by Regions
2.2.1 Lysosomal Disease Treatment Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Lysosomal Disease Treatment Historic Market Share by Regions (2016-2021)
2.2.3 Lysosomal Disease Treatment Forecasted Market Size by Regions (2022-2027)
2.3 Lysosomal Disease Treatment Industry Dynamic
2.3.1 Lysosomal Disease Treatment Market Trends
2.3.2 Lysosomal Disease Treatment Market Drivers
2.3.3 Lysosomal Disease Treatment Market Challenges
2.3.4 Lysosomal Disease Treatment Market Restraints

3 Competition Landscape by Key Players
3.1 Global Top Lysosomal Disease Treatment Players by Revenue
3.1.1 Global Top Lysosomal Disease Treatment Players by Revenue (2016-2021)
3.1.2 Global Lysosomal Disease Treatment Revenue Market Share by Players (2016-2021)
3.2 Global Lysosomal Disease Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Lysosomal Disease Treatment Revenue
3.4 Global Lysosomal Disease Treatment Market Concentration Ratio
3.4.1 Global Lysosomal Disease Treatment Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Lysosomal Disease Treatment Revenue in 2020
3.5 Lysosomal Disease Treatment Key Players Head office and Area Served
3.6 Key Players Lysosomal Disease Treatment Product Solution and Service
3.7 Date of Enter into Lysosomal Disease Treatment Market
3.8 Mergers & Acquisitions, Expansion Plans

4 Lysosomal Disease Treatment Breakdown Data by Type
4.1 Global Lysosomal Disease Treatment Historic Market Size by Type (2016-2021)
4.2 Global Lysosomal Disease Treatment Forecasted Market Size by Type (2022-2027)

5 Lysosomal Disease Treatment Breakdown Data by Application
5.1 Global Lysosomal Disease Treatment Historic Market Size by Application (2016-2021)
5.2 Global Lysosomal Disease Treatment Forecasted Market Size by Application (2022-2027)

6 North America
6.1 North America Lysosomal Disease Treatment Market Size (2016-2027)
6.2 North America Lysosomal Disease Treatment Market Size by Type
6.2.1 North America Lysosomal Disease Treatment Market Size by Type (2016-2021)
6.2.2 North America Lysosomal Disease Treatment Market Size by Type (2022-2027)
6.2.3 North America Lysosomal Disease Treatment Market Size by Type (2016-2027)
6.3 North America Lysosomal Disease Treatment Market Size by Application
6.3.1 North America Lysosomal Disease Treatment Market Size by Application (2016-2021)
6.3.2 North America Lysosomal Disease Treatment Market Size by Application (2022-2027)
6.3.3 North America Lysosomal Disease Treatment Market Size by Application (2016-2027)
6.4 North America Lysosomal Disease Treatment Market Size by Country
6.4.1 North America Lysosomal Disease Treatment Market Size by Country (2016-2021)
6.4.2 North America Lysosomal Disease Treatment Market Size by Country (2022-2027)
6.4.3 United States
6.4.4 Canada

7 Europe
7.1 Europe Lysosomal Disease Treatment Market Size (2016-2027)
7.2 Europe Lysosomal Disease Treatment Market Size by Type
7.2.1 Europe Lysosomal Disease Treatment Market Size by Type (2016-2021)
7.2.2 Europe Lysosomal Disease Treatment Market Size by Type (2022-2027)
7.2.3 Europe Lysosomal Disease Treatment Market Size by Type (2016-2027)
7.3 Europe Lysosomal Disease Treatment Market Size by Application
7.3.1 Europe Lysosomal Disease Treatment Market Size by Application (2016-2021)
7.3.2 Europe Lysosomal Disease Treatment Market Size by Application (2022-2027)
7.3.3 Europe Lysosomal Disease Treatment Market Size by Application (2016-2027)
7.4 Europe Lysosomal Disease Treatment Market Size by Country
7.4.1 Europe Lysosomal Disease Treatment Market Size by Country (2016-2021)
7.4.2 Europe Lysosomal Disease Treatment Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic

8 Asia-Pacific
8.1 Asia-Pacific Lysosomal Disease Treatment Market Size (2016-2027)
8.2 Asia-Pacific Lysosomal Disease Treatment Market Size by Type
8.2.1 Asia-Pacific Lysosomal Disease Treatment Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Lysosomal Disease Treatment Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Lysosomal Disease Treatment Market Size by Type (2016-2027)
8.3 Asia-Pacific Lysosomal Disease Treatment Market Size by Application
8.3.1 Asia-Pacific Lysosomal Disease Treatment Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Lysosomal Disease Treatment Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Lysosomal Disease Treatment Market Size by Application (2016-2027)
8.4 Asia-Pacific Lysosomal Disease Treatment Market Size by Region
8.4.1 Asia-Pacific Lysosomal Disease Treatment Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Lysosomal Disease Treatment Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia

9 Latin America
9.1 Latin America Lysosomal Disease Treatment Market Size (2016-2027)
9.2 Latin America Lysosomal Disease Treatment Market Size by Type
9.2.1 Latin America Lysosomal Disease Treatment Market Size by Type (2016-2021)
9.2.2 Latin America Lysosomal Disease Treatment Market Size by Type (2022-2027)
9.2.3 Latin America Lysosomal Disease Treatment Market Size by Type (2016-2027)
9.3 Latin America Lysosomal Disease Treatment Market Size by Application
9.3.1 Latin America Lysosomal Disease Treatment Market Size by Application (2016-2021)
9.3.2 Latin America Lysosomal Disease Treatment Market Size by Application (2022-2027)
9.3.3 Latin America Lysosomal Disease Treatment Market Size by Application (2016-2027)
9.4 Latin America Lysosomal Disease Treatment Market Size by Country
9.4.1 Latin America Lysosomal Disease Treatment Market Size by Country (2016-2021)
9.4.2 Latin America Lysosomal Disease Treatment Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil

10 Middle East & Africa
10.1 Middle East & Africa Lysosomal Disease Treatment Market Size (2016-2027)
10.2 Middle East & Africa Lysosomal Disease Treatment Market Size by Type
10.2.1 Middle East & Africa Lysosomal Disease Treatment Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Lysosomal Disease Treatment Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Lysosomal Disease Treatment Market Size by Type (2016-2027)
10.3 Middle East & Africa Lysosomal Disease Treatment Market Size by Application
10.3.1 Middle East & Africa Lysosomal Disease Treatment Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Lysosomal Disease Treatment Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Lysosomal Disease Treatment Market Size by Application (2016-2027)
10.4 Middle East & Africa Lysosomal Disease Treatment Market Size by Country
10.4.1 Middle East & Africa Lysosomal Disease Treatment Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Lysosomal Disease Treatment Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE

11 Key Players Profiles
11.1 Astellas Pharma
11.1.1 Astellas Pharma Company Details
11.1.2 Astellas Pharma Business Overview
11.1.3 Astellas Pharma Lysosomal Disease Treatment Introduction
11.1.4 Astellas Pharma Revenue in Lysosomal Disease Treatment Business (2016-2021)
11.1.5 Astellas Pharma Recent Development
11.2 Astrazeneca
11.2.1 Astrazeneca Company Details
11.2.2 Astrazeneca Business Overview
11.2.3 Astrazeneca Lysosomal Disease Treatment Introduction
11.2.4 Astrazeneca Revenue in Lysosomal Disease Treatment Business (2016-2021)
11.2.5 Astrazeneca Recent Development
11.3 Actelion Pharmaceuticals Ltd.
11.3.1 Actelion Pharmaceuticals Ltd. Company Details
11.3.2 Actelion Pharmaceuticals Ltd. Business Overview
11.3.3 Actelion Pharmaceuticals Ltd. Lysosomal Disease Treatment Introduction
11.3.4 Actelion Pharmaceuticals Ltd. Revenue in Lysosomal Disease Treatment Business (2016-2021)
11.3.5 Actelion Pharmaceuticals Ltd. Recent Development
11.4 Eli Lilly and Co.
11.4.1 Eli Lilly and Co. Company Details
11.4.2 Eli Lilly and Co. Business Overview
11.4.3 Eli Lilly and Co. Lysosomal Disease Treatment Introduction
11.4.4 Eli Lilly and Co. Revenue in Lysosomal Disease Treatment Business (2016-2021)
11.4.5 Eli Lilly and Co. Recent Development
11.5 Merck & Co.
11.5.1 Merck & Co. Company Details
11.5.2 Merck & Co. Business Overview
11.5.3 Merck & Co. Lysosomal Disease Treatment Introduction
11.5.4 Merck & Co. Revenue in Lysosomal Disease Treatment Business (2016-2021)
11.5.5 Merck & Co. Recent Development
11.6 Novo Nordisk A/S
11.6.1 Novo Nordisk A/S Company Details
11.6.2 Novo Nordisk A/S Business Overview
11.6.3 Novo Nordisk A/S Lysosomal Disease Treatment Introduction
11.6.4 Novo Nordisk A/S Revenue in Lysosomal Disease Treatment Business (2016-2021)
11.6.5 Novo Nordisk A/S Recent Development
11.7 Shire
11.7.1 Shire Company Details
11.7.2 Shire Business Overview
11.7.3 Shire Lysosomal Disease Treatment Introduction
11.7.4 Shire Revenue in Lysosomal Disease Treatment Business (2016-2021)
11.7.5 Shire Recent Development
11.8 Pfizer
11.8.1 Pfizer Company Details
11.8.2 Pfizer Business Overview
11.8.3 Pfizer Lysosomal Disease Treatment Introduction
11.8.4 Pfizer Revenue in Lysosomal Disease Treatment Business (2016-2021)
11.8.5 Pfizer Recent Development
11.9 Sanofi
11.9.1 Sanofi Company Details
11.9.2 Sanofi Business Overview
11.9.3 Sanofi Lysosomal Disease Treatment Introduction
11.9.4 Sanofi Revenue in Lysosomal Disease Treatment Business (2016-2021)
11.9.5 Sanofi Recent Development
11.10 BioMarin
11.10.1 BioMarin Company Details
11.10.2 BioMarin Business Overview
11.10.3 BioMarin Lysosomal Disease Treatment Introduction
11.10.4 BioMarin Revenue in Lysosomal Disease Treatment Business (2016-2021)
11.10.5 BioMarin Recent Development

12 Analyst’s Viewpoints/Conclusions

13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Tables
Table 1. Global Lysosomal Disease Treatment Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
Table 2. Key Players of Hematopoietic Stem Cell Transplantation
Table 3. Key Players of Enzyme Replacement Therapy
Table 4. Key Players of Substrate Reduction
Table 5. Key Players of Chaperone Therapies
Table 6. Global Lysosomal Disease Treatment Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
Table 7. Global Lysosomal Disease Treatment Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
Table 8. Global Lysosomal Disease Treatment Market Size by Regions (2016-2021) & (US$ Million)
Table 9. Global Lysosomal Disease Treatment Market Share by Regions (2016-2021)
Table 10. Global Lysosomal Disease Treatment Forecasted Market Size by Regions (2022-2027) & (US$ Million)
Table 11. Global Lysosomal Disease Treatment Market Share by Regions (2022-2027)
Table 12. Lysosomal Disease Treatment Market Trends
Table 13. Lysosomal Disease Treatment Market Drivers
Table 14. Lysosomal Disease Treatment Market Challenges
Table 15. Lysosomal Disease Treatment Market Restraints
Table 16. Global Lysosomal Disease Treatment Revenue by Players (2016-2021) & (US$ Million)
Table 17. Global Lysosomal Disease Treatment Market Share by Players (2016-2021)
Table 18. Global Top Lysosomal Disease Treatment Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Lysosomal Disease Treatment as of 2020)
Table 19. Ranking of Global Top Lysosomal Disease Treatment Companies by Revenue (US$ Million) in 2020
Table 20. Global 5 Largest Players Market Share by Lysosomal Disease Treatment Revenue (CR5 and HHI) & (2016-2021)
Table 21. Key Players Headquarters and Area Served
Table 22. Key Players Lysosomal Disease Treatment Product Solution and Service
Table 23. Date of Enter into Lysosomal Disease Treatment Market
Table 24. Mergers & Acquisitions, Expansion Plans
Table 25. Global Lysosomal Disease Treatment Market Size by Type (2016-2021) (US$ Million)
Table 26. Global Lysosomal Disease Treatment Revenue Market Share by Type (2016-2021)
Table 27. Global Lysosomal Disease Treatment Forecasted Market Size by Type (2022-2027) (US$ Million)
Table 28. Global Lysosomal Disease Treatment Revenue Market Share by Type (2022-2027) & (US$ Million)
Table 29. Global Lysosomal Disease Treatment Market Size Share by Application (2016-2021) & (US$ Million)
Table 30. Global Lysosomal Disease Treatment Revenue Market Share by Application (2016-2021)
Table 31. Global Lysosomal Disease Treatment Forecasted Market Size by Application (2022-2027) (US$ Million)
Table 32. Global Lysosomal Disease Treatment Revenue Market Share by Application (2022-2027) & (US$ Million)
Table 33. North America Lysosomal Disease Treatment Market Size by Type (2016-2021) (US$ Million)
Table 34. North America Lysosomal Disease Treatment Market Size by Type (2022-2027) & (US$ Million)
Table 35. North America Lysosomal Disease Treatment Market Size by Application (2016-2021) (US$ Million)
Table 36. North America Lysosomal Disease Treatment Market Size by Application (2022-2027) & (US$ Million)
Table 37. North America Lysosomal Disease Treatment Market Size by Country (2016-2021) & (US$ Million)
Table 38. North America Lysosomal Disease Treatment Market Size by Country (2022-2027) & (US$ Million)
Table 39. Europe Lysosomal Disease Treatment Market Size by Type (2016-2021) (US$ Million)
Table 40. Europe Lysosomal Disease Treatment Market Size by Type (2022-2027) & (US$ Million)
Table 41. Europe Lysosomal Disease Treatment Market Size by Application (2016-2021) (US$ Million)
Table 42. Europe Lysosomal Disease Treatment Market Size by Application (2022-2027) & (US$ Million)
Table 43. Europe Lysosomal Disease Treatment Market Size by Country (2016-2021) & (US$ Million)
Table 44. Europe Lysosomal Disease Treatment Market Size by Country (2022-2027) & (US$ Million)
Table 45. Asia-Pacific Lysosomal Disease Treatment Market Size by Type (2016-2021) (US$ Million)
Table 46. Asia-Pacific Lysosomal Disease Treatment Market Size by Type (2022-2027) & (US$ Million)
Table 47. Asia-Pacific Lysosomal Disease Treatment Market Size by Application (2016-2021) (US$ Million)
Table 48. Asia-Pacific Lysosomal Disease Treatment Market Size by Application (2022-2027) & (US$ Million)
Table 49. Asia-Pacific Lysosomal Disease Treatment Market Size by Region (2016-2021) & (US$ Million)
Table 50. Asia-Pacific Lysosomal Disease Treatment Market Size by Region (2022-2027) & (US$ Million)
Table 51. Latin America Lysosomal Disease Treatment Market Size by Type (2016-2021) (US$ Million)
Table 52. Latin America Lysosomal Disease Treatment Market Size by Type (2022-2027) & (US$ Million)
Table 53. Latin America Lysosomal Disease Treatment Market Size by Application (2016-2021) (US$ Million)
Table 54. Latin America Lysosomal Disease Treatment Market Size by Application (2022-2027) & (US$ Million)
Table 55. Latin America Lysosomal Disease Treatment Market Size by Country (2016-2021) & (US$ Million)
Table 56. Latin America Lysosomal Disease Treatment Market Size by Country (2022-2027) & (US$ Million)
Table 57. Middle East & Africa Lysosomal Disease Treatment Market Size by Type (2016-2021) (US$ Million)
Table 58. Middle East & Africa Lysosomal Disease Treatment Market Size by Type (2022-2027) & (US$ Million)
Table 59. Middle East & Africa Lysosomal Disease Treatment Market Size by Application (2016-2021) (US$ Million)
Table 60. Middle East & Africa Lysosomal Disease Treatment Market Size by Application (2022-2027) & (US$ Million)
Table 61. Middle East & Africa Lysosomal Disease Treatment Market Size by Country (2016-2021) & (US$ Million)
Table 62. Middle East & Africa Lysosomal Disease Treatment Market Size by Country (2022-2027) & (US$ Million)
Table 63. Astellas Pharma Company Details
Table 64. Astellas Pharma Business Overview
Table 65. Astellas Pharma Lysosomal Disease Treatment Product
Table 66. Astellas Pharma Revenue in Lysosomal Disease Treatment Business (2016-2021) & (US$ Million)
Table 67. Astellas Pharma Recent Development
Table 68. Astrazeneca Company Details
Table 69. Astrazeneca Business Overview
Table 70. Astrazeneca Lysosomal Disease Treatment Product
Table 71. Astrazeneca Revenue in Lysosomal Disease Treatment Business (2016-2021) & (US$ Million)
Table 72. Astrazeneca Recent Development
Table 73. Actelion Pharmaceuticals Ltd. Company Details
Table 74. Actelion Pharmaceuticals Ltd. Business Overview
Table 75. Actelion Pharmaceuticals Ltd. Lysosomal Disease Treatment Product
Table 76. Actelion Pharmaceuticals Ltd. Revenue in Lysosomal Disease Treatment Business (2016-2021) & (US$ Million)
Table 77. Actelion Pharmaceuticals Ltd. Recent Development
Table 78. Eli Lilly and Co. Company Details
Table 79. Eli Lilly and Co. Business Overview
Table 80. Eli Lilly and Co. Lysosomal Disease Treatment Product
Table 81. Eli Lilly and Co. Revenue in Lysosomal Disease Treatment Business (2016-2021) & (US$ Million)
Table 82. Eli Lilly and Co. Recent Development
Table 83. Merck & Co. Company Details
Table 84. Merck & Co. Business Overview
Table 85. Merck & Co. Lysosomal Disease Treatment Product
Table 86. Merck & Co. Revenue in Lysosomal Disease Treatment Business (2016-2021) & (US$ Million)
Table 87. Merck & Co. Recent Development
Table 88. Novo Nordisk A/S Company Details
Table 89. Novo Nordisk A/S Business Overview
Table 90. Novo Nordisk A/S Lysosomal Disease Treatment Product
Table 91. Novo Nordisk A/S Revenue in Lysosomal Disease Treatment Business (2016-2021) & (US$ Million)
Table 92. Novo Nordisk A/S Recent Development
Table 93. Shire Company Details
Table 94. Shire Business Overview
Table 95. Shire Lysosomal Disease Treatment Product
Table 96. Shire Revenue in Lysosomal Disease Treatment Business (2016-2021) & (US$ Million)
Table 97. Shire Recent Development
Table 98. Pfizer Company Details
Table 99. Pfizer Business Overview
Table 100. Pfizer Revenue in Lysosomal Disease Treatment Business (2016-2021) & (US$ Million)
Table 101. Pfizer Recent Development
Table 102. Sanofi Company Details
Table 103. Sanofi Business Overview
Table 104. Sanofi Lysosomal Disease Treatment Product
Table 105. Sanofi Revenue in Lysosomal Disease Treatment Business (2016-2021) & (US$ Million)
Table 106. Sanofi Recent Development
Table 107. BioMarin Company Details
Table 108. BioMarin Business Overview
Table 109. BioMarin Lysosomal Disease Treatment Product
Table 110. BioMarin Revenue in Lysosomal Disease Treatment Business (2016-2021) & (US$ Million)
Table 111. BioMarin Recent Development
Table 112. Research Programs/Design for This Report
Table 113. Key Data Information from Secondary Sources
Table 114. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Lysosomal Disease Treatment Market Share by Type: 2020 VS 2027
Figure 2. Hematopoietic Stem Cell Transplantation Features
Figure 3. Enzyme Replacement Therapy Features
Figure 4. Substrate Reduction Features
Figure 5. Chaperone Therapies Features
Figure 6. Global Lysosomal Disease Treatment Market Share by Application: 2020 VS 2027
Figure 7. Hospitals Case Studies
Figure 8. Clinics Case Studies
Figure 9. Stem Cell Transplant Center Case Studies
Figure 10. Research Organizations Case Studies
Figure 11. Others Case Studies
Figure 12. Lysosomal Disease Treatment Report Years Considered
Figure 13. Global Lysosomal Disease Treatment Market Size (US$ Million), Year-over-Year: 2016-2027
Figure 14. Global Lysosomal Disease Treatment Market Size (US$ Million), 2016 VS 2021 VS 2027
Figure 15. Global Lysosomal Disease Treatment Market Share by Regions: 2020 VS 2027
Figure 16. Global Lysosomal Disease Treatment Market Share by Regions (2022-2027)
Figure 17. Global Lysosomal Disease Treatment Market Share by Players in 2020
Figure 18. Global Top Lysosomal Disease Treatment Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Lysosomal Disease Treatment as of 2020
Figure 19. The Top 10 and 5 Players Market Share by Lysosomal Disease Treatment Revenue in 2020
Figure 20. Global Lysosomal Disease Treatment Revenue Market Share by Type (2016-2021)
Figure 21. Global Lysosomal Disease Treatment Revenue Market Share by Type (2022-2027)
Figure 22. North America Lysosomal Disease Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 23. North America Lysosomal Disease Treatment Market Share by Type (2016-2027)
Figure 24. North America Lysosomal Disease Treatment Market Share by Application (2016-2027)
Figure 25. North America Lysosomal Disease Treatment Market Share by Country (2016-2027)
Figure 26. United States Lysosomal Disease Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 27. Canada Lysosomal Disease Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 28. Europe Lysosomal Disease Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 29. Europe Lysosomal Disease Treatment Market Share by Type (2016-2027)
Figure 30. Europe Lysosomal Disease Treatment Market Share by Application (2016-2027)
Figure 31. Europe Lysosomal Disease Treatment Market Share by Country (2016-2027)
Figure 32. Germany Lysosomal Disease Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 33. France Lysosomal Disease Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 34. U.K. Lysosomal Disease Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 35. Italy Lysosomal Disease Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 36. Russia Lysosomal Disease Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 37. Nordic Lysosomal Disease Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 38. Asia-Pacific Lysosomal Disease Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 39. Asia-Pacific Lysosomal Disease Treatment Market Share by Type (2016-2027)
Figure 40. Asia-Pacific Lysosomal Disease Treatment Market Share by Application (2016-2027)
Figure 41. Asia-Pacific Lysosomal Disease Treatment Market Share by Region (2016-2027)
Figure 42. China Lysosomal Disease Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 43. Japan Lysosomal Disease Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 44. South Korea Lysosomal Disease Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 45. Southeast Asia Lysosomal Disease Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 46. India Lysosomal Disease Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 47. Australia Lysosomal Disease Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 48. Latin America Lysosomal Disease Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 49. Latin America Lysosomal Disease Treatment Market Share by Type (2016-2027)
Figure 50. Latin America Lysosomal Disease Treatment Market Share by Application (2016-2027)
Figure 51. Latin America Lysosomal Disease Treatment Market Share by Country (2016-2027)
Figure 52. Mexico Lysosomal Disease Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 53. Brazil Lysosomal Disease Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 54. Middle East & Africa Lysosomal Disease Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 55. Middle East & Africa Lysosomal Disease Treatment Market Share by Type (2016-2027)
Figure 56. Middle East & Africa Lysosomal Disease Treatment Market Share by Application (2016-2027)
Figure 57. Middle East & Africa Lysosomal Disease Treatment Market Share by Country (2016-2027)
Figure 58. Turkey Lysosomal Disease Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 59. Saudi Arabia Lysosomal Disease Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 60. UAE Lysosomal Disease Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 61. Astellas Pharma Revenue Growth Rate in Lysosomal Disease Treatment Business (2016-2021)
Figure 62. Astrazeneca Revenue Growth Rate in Lysosomal Disease Treatment Business (2016-2021)
Figure 63. Actelion Pharmaceuticals Ltd. Revenue Growth Rate in Lysosomal Disease Treatment Business (2016-2021)
Figure 64. Eli Lilly and Co. Revenue Growth Rate in Lysosomal Disease Treatment Business (2016-2021)
Figure 65. Merck & Co. Revenue Growth Rate in Lysosomal Disease Treatment Business (2016-2021)
Figure 66. Novo Nordisk A/S Revenue Growth Rate in Lysosomal Disease Treatment Business (2016-2021)
Figure 67. Shire Revenue Growth Rate in Lysosomal Disease Treatment Business (2016-2021)
Figure 68. Pfizer Revenue Growth Rate in Lysosomal Disease Treatment Business (2016-2021)
Figure 69. Sanofi Revenue Growth Rate in Lysosomal Disease Treatment Business (2016-2021)
Figure 70. BioMarin Revenue Growth Rate in Lysosomal Disease Treatment Business (2016-2021)
Figure 71. Bottom-up and Top-down Approaches for This Report
Figure 72. Data Triangulation
Figure 73. Key Executives Interviewed

以下、関連資料のご紹介

世界のリソソーム蓄積症治療市場規模・現状・予測（2021年-2027年）

Global Lysosomal Storage Disease Treatment Market Size, Status and Forecast 2021-2027
QFJ1-4451 2021年6月 95Pages
QYResearch社発行の本調査レポートでは、リソソーム蓄積症治療の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（酵素補充療法、幹細胞移植、基質減少療法、その他）、用途別市場規模（病院、クリニック、幹細胞移植センター、研究機関、その他）、主要地域...

世界のフォン・ヴィレブランド病治療市場規模・現状・予測（2021年-2027年）

Global Von Willebrand Disease Treatment Market Size, Status and Forecast 2021-2027
QFJ1-5033 2021年6月 100Pages
QYResearch社発行の本調査レポートでは、フォン・ヴィレブランド病治療の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（Veyvondi、Humate-P、Alphanate、その他）、用途別市場規模（病院、診療所、その他）、主要地域別市場規模...

世界のペイロニー病治療市場規模・現状・予測（2021年-2027年）

Global Peyronie’s Disease Treatment Market Size, Status and Forecast 2021-2027
QFJ1-4696 2021年6月 89Pages
QYResearch社発行の本調査レポートでは、ペイロニー病治療の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（治療薬、手術）、用途別市場規模（病院、ドラッグストア）、主要地域別市場規模（北米、アメリカ、欧州、アジア、日本、中国、韓国、インド、東南...

世界のバッテン病治療市場規模・現状・予測（2021年-2027年）

Global Batten Disease Treatment Market Size, Status and Forecast 2021-2027
QFJ1-3891 2021年6月 96Pages
QYResearch社発行の本調査レポートでは、バッテン病治療の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（作業療法、理学療法）、用途別市場規模（乳児NCL、後期乳児NCL、少年NCL、成人NCL）、主要地域別市場規模（北米、アメリカ、欧州、アジ...

世界の多発性嚢胞腎治療薬市場規模・現状・予測（2021年-2027年）

Global Polycystic Kidney Disease Treatment Drugs Market Size, Status and Forecast 2021-2027
QFJ1-4730 2021年6月 99Pages
QYResearch社発行の本調査レポートでは、多発性嚢胞腎治療薬の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（ANG-3070、CIM-2、CR-8、その他）、用途別市場規模（常染色体優性多発性嚢胞腎（ADPKD）、常染色体劣性多発性嚢胞腎（A...

世界のアジソン病用治療市場規模・現状・予測（2021年-2027年）

Global Addison's Disease Treatment Market Size, Status and Forecast 2021-2027
QFJ1-3763 2021年6月 98Pages
QYResearch社発行の本調査レポートでは、アジソン病用治療の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（経口コルチコステロイド、コルチコステロイド注射）、用途別市場規模（病院、診療所、その他）、主要地域別市場規模（北米、アメリカ、欧州、アジ...

世界のICAD (頭蓋内アテローム性動脈硬化症) 病理学治療市場規模・現状・予測（2021年-2027年）

Global ICAD (Intracranial Atherosclerotic Disease) Pathology Treatment Market Size, Status and Forecast 2021-2027
QFJ1-5203 2021年6月 98Pages
QYResearch社発行の本調査レポートでは、ICAD (頭蓋内アテローム性動脈硬化症) 病理学治療の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（ステント、PTAバルーン）、用途別市場規模（病院、診療所、その他）、主要地域別市場規模（北米、アメ...

世界の認知症＆アルツハイマー病治療市場規模・現状・予測（2021年-2027年）

Global Dementia and Alzheimer’s Disease Treatment Market Size, Status and Forecast 2021-2027
QFJ1-5693 2021年6月 108Pages
QYResearch社発行の本調査レポートでは、認知症＆アルツハイマー病治療の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（コリンエステラーゼ阻害剤、メマンチン、併用薬）、用途別市場規模（病院、診療所）、主要地域別市場規模（北米、アメリカ、欧州、ア...

世界の非びらん性胃食道逆流症治療市場規模・現状・予測（2021年-2027年）

Global Nonerosive Reflux Disease Treatment Market Size, Status and Forecast 2021-2027
QFJ1-5889 2021年6月 97Pages
QYResearch社発行の本調査レポートでは、非びらん性胃食道逆流症治療の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（プロトンポンプ阻害剤、H2受容体拮抗薬、制酸剤、その他）、用途別市場規模（小売薬局、病院薬局、オンライン薬局）、主要地域別市場...

世界のエルドハイムチェスター病治療法市場規模・現状・予測（2021年-2027年）

Global Erdheim Chester Disease Treatment Market Size, Status and Forecast 2021-2027
QFJ1-4203 2021年6月 96Pages
QYResearch社発行の本調査レポートでは、エルドハイムチェスター病治療法の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（免疫療法、化学療法）、用途別市場規模（病院、診療所、その他）、主要地域別市場規模（北米、アメリカ、欧州、アジア、日本、中国...

世界のリソソーム蓄積症治療市場規模・現状・予測（2021年-2027年） Lysosomal storage disease (LTD) is caused by defect in lysosomal functions and degradation pathway. It is caused by progressive accumulation of metabolites. LTD is a rare inherited metabolic disorder. Market Analysis and Insights: Global Lysosomal Storage Disease Treatment Market The global Lysosoma…
世界の脱毛症幹細胞＆多血小板血漿（PRP）治療市場規模・現状・予測（2021年-2027年） Platelet-rich plasma (PRP) has emerged as a new treatment modality in regenerative plastic surgery, and preliminary evidence suggests that it might have a beneficial role in hair regrowth. Market Analysis and Insights: Global Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Market The gl…
造血幹細胞移植（HSCT）のグローバル市場調査 2019年 The global Hematopoietic Stem Cell Transplantation (HSCT) market was valued at million US$ in 2018 and will reach million US$ by the end of 2025, growing at a CAGR of during 2019-2025. This report focuses on Hematopoietic Stem Cell Transplantation (HSCT) volume and value at global level, regional le…
世界の自家幹細胞＆非幹細胞系治療法市場規模・現状・予測（2021年-2027年） Market Analysis and Insights: Global Autologous Stem Cell and Non-Stem Cell Based Therapies Market The global Autologous Stem Cell and Non-Stem Cell Based Therapies market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027. With industry…
世界の脱毛症幹細胞治療市場規模・現状・予測（2021年-2027年） The stem cells, which are stimulated by the drug, replenish or restore cells associated with the induction of hair growth. Market Analysis and Insights: Global Stem Cell Alopecia Treatment Market The global Stem Cell Alopecia Treatment market size is projected to reach US$ XX million by 2027, from U…